| Item type |
学内発行雑誌 / Departmental Bulletin Paper(1) |
| 公開日 |
2018-09-03 |
| タイトル |
|
|
タイトル |
Safety and Efficacy of Adenosine 5’-Triphosphate as a Hyperemic Agent for the Assessment of Peripheral Fractional Flow Reserve |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ |
departmental bulletin paper |
| 著者 |
MAEDA, Atsuo
TASHIRO, Kazuma
SASAI, Masahiro
MORI, Hiroyoshi
SATO, Tokutada
HAYASHI, Munetaka
SUZUKI, Hiroshi
|
| 書誌情報 |
The Showa University journal of medical sciences
巻 30,
号 2,
p. 151-158,
発行日 2018-06
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
The myocardial fractional flow reserve （FFR） is a useful measure of physiological stenosis in the coronary artery. Previous reports have identified peripheral FFR （pFFR） as another useful measure in peripheral artery disease （PAD）; however, the vasodilators used to obtain maximal hyperemia varied among studies. The present study was conducted to identify the ideal vasodilator and vasodilator dose for pFFR assessment. We enrolled 24 patients with 26 lesions, comprising 14 lesions of the iliac artery and 12 lesions of the superficial femoral artery （SFA）. After measuring the mean aortic pressure （Pa）, the guidewire was advanced across the lesion and the mean distal pressure （Pd） was measured at the baseline Pd/Pa. A 100-?g dose of adenosine 5’-triphosphate （ATP） was then administered to obtain a pFFR with a washout interval of 5 to 10 minutes. Next, 200?g of ATP, 10mg of papaverine hydrochloride, or 1.5mg of isosorbide dinitrate was administered before the final pFFR measurement. The baseline Pd/Pa （0.88±0.08） was significantly decreased after each vasodilator （P＜0.0001）, but there was no significant difference in pFFR among vasodilators （P＝0.7569）. The study was discontinued in two patients with SFA lesions due to decreased systemic blood pressure after vasodilator administration. The hyperemic efficacy of 100?g of ATP administered intra-arterially was similar to the efficacies of 200?g of ATP, 10mg of papaverine hydrochloride, and 1.5mg of isosorbide dinitrate. Given the milder side effects of ATP versus other vasodilators, an intra-arterial dose of ATP 100?g may be optimal as a first-line agent for pFFR measurement. |
| DOI |
|
|
|
関連識別子 |
10.15369/sujms.30.151 |
| 出版者 |
|
|
出版者 |
Showa University Society |
| ISSN |
|
|
収録物識別子 |
0915-6380 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
S30_151.pdf (399.0 kB)
